局限性低、中、高危前列腺癌半腺体冷冻消融:5年肿瘤学与功能结局
回顾160例连续接受半腺体冷冻消融的局限性前列腺癌患者,中位随访40个月,5年无治疗失败生存率85%、无生化失败生存率62%、无临床显著前列腺癌生存率89%,无转移生存率100%,保留控尿97%、勃起功能73%。基线PSA较高独立预测治疗失败、生化失败、复发及根治性治疗。
要点
- 5年无治疗失败生存率85%,无生化失败生存率62%,无临床显著前列腺癌生存率89%。
- 5年无转移生存率100%,无直肠瘘或死亡,保留控尿97%、勃起功能73%。
- 基线PSA较高独立预测治疗失败、生化失败、复发及根治性治疗。
核心结论
- 半腺体冷冻消融治疗局限性前列腺癌提供有效的中期肿瘤学结局,控尿和勃起功能良好。
- 基线PSA较高的患者生化失败、癌症复发和治疗失败风险增加。
研究设计与样本
- 回顾160例连续接受半腺体冷冻消融的局限性前列腺癌患者的记录。
- 复发和/或残留临床显著前列腺癌定义为随访活检Grade Group 2或以上。
- 生化失败采用Phoenix标准即PSA最低值加2 ng/ml定义。
主要发现
- 患者中位年龄67岁,基线PSA 6.3 ng/ml,随访40个月。
- 131例(82%)为D'Amico中危(66%)或高危(16%)前列腺癌。
- 5年无治疗失败生存率85%,无生化失败生存率62%,无临床显著前列腺癌生存率89%。
- 5年无转移生存率100%,保留控尿97%、勃起功能73%,无直肠瘘或死亡。
关键数值与推荐
- 基线PSA较高独立预测治疗失败(p<0.001)、生化失败(p=0.048)、复发和根治性治疗(p<0.01)。
- Grade Group 3或以上独立预测治疗失败(p=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated 5-year oncologic and functional outcomes of hemigland cryoablation of localized prostate cancer. MATERIALS AND METHODS: We reviewed the records of 160 consecutive men who underwent hemigland cryoablation of localized prostate cancer. Recurrent and/or residual clinically significant prostate cancer was defined as Grade Group 2 or greater on followup biopsy. A prostate specific antigen nadir plus 2 ng/ml according to the Phoenix criteria was used to define biochemical failure. Radical treatment was defined as any whole gland therapy. Treatment failure was defined as any radical and/or whole gland treatment, systemic therapy initiation, metastasis or prostate cancer specific mortality. The study primary end point was treatment failure-free survival. The secondary end points were survival free of biochemical failure, clinically significant prostate cancer and radical treatment. Followup biopsy and functional outcomes were also evaluated. Statistical analysis included the Kaplan-Meier method, and univariate and multivariable Cox and logistic regression with significance considered at p <0.05. RESULTS: Median patient age was 67 years, baseline prostate specific antigen was 6.3 ng/ml and followup was 40 months. A total of 131 patients (82%) had D'Amico intermediate (66%) or high risk (16%) prostate cancer. At 5 years the treatment failure-free survival rate was 85%, the biochemical failure-free survival rate was 62% and the survival rate free of clinically significant prostate cancer was 89%. Higher baseline prostate specific antigen independently predicted treatment failure (p <0.001), biochemical failure (p=0.048), recurrence and radical treatment (p <0.01). Grade Group 3 or greater independently predicted treatment failure (p=0.04). The metastasis-free survival rate was 100% at 5 years. Pad-free continence and potency (erections sufficient for intercourse) were retained in 97% and 73% of patients, respectively. There was no rectal fistula or mortality. CONCLUSIONS: Hemigland cryoablation of localized prostate cancer provides effective midterm oncologic outcomes with good continence and potency. Patients with higher baseline prostate specific antigen are at increased risk for biochemical failure, recurrent cancer and treatment failure.
引用
- Oishi M, Gill IS, Tafuri A, et al. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. J Urol. 2019. PMID: 31347953. doi:10.1097/JU.0000000000000456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。